Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair

AUTOR(ES)

Einhorn, Thomas A

FONTE

BioMed Central

RESUMO

Prostaglandins are important mediators of bone repair, and cyclooxygenases are required for prostaglandin production. Data from animal studies suggest that both non-specific and specific inhibitors of cyclooxygenases impair fracture healing but that this is due to the inhibition of COX-2 and not COX-1. Although these data raise concerns about the use of COX-2-specific inhibitors as anti-inflammatory or anti-analgesic drugs in patients undergoing bone repair, clinical reports have been inconclusive. Because animal data suggest that the effects of COX-2 inhibitors are both dose-dependent and reversible, in the absence of scientifically sound clinical evidence it is suggested that physicians consider short-term administration or other drugs in the management of these patients.

Documentos Relacionados

• COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease
• Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
• COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred
• COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients
• Post-Training Cyclooxygenase-2 (COX-2) Inhibition Impairs Memory Consolidation